Effect of gelatin on heparin regulation of cytokine release from hyaluronan-based hydrogels

Drug Delivery

Volumn 15, Issue 6, 2008, Pages 389-397

  Peattie, Robert A ^a   Pike, Daniel B ^a   Yu, Bolan ^b   Cai, Shenshen ^b   Shu, Xiao Zheng ^b   Prestwich, Glenn D ^b   Firpo, Matthew A ^c   Fisher, Robert J ^d  

^a Tufts University   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

Angiogenesis; Controlled Drug Release; Cytokine; Glycosaminoglycans; Growth Factors

Indexed keywords

ANGIOPOIETIN 1; BASIC FIBROBLAST GROWTH FACTOR; CYTOKINE; GELATIN; GROWTH FACTOR; HEPARIN; HYALURONIC ACID; KERATINOCYTE GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR AA; THIOL; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; HYDROGEL; IN VITRO STUDY; IN VIVO STUDY; KINETICS; MALE; MASS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; VASCULARIZATION;

ANGIOGENESIS INDUCING AGENTS; ANGIOPOIETIN-1; ANIMALS; CATTLE; CYTOKINES; DRUG IMPLANTS; EAR; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 7; GELATIN; GLYCOSAMINOGLYCANS; HEPARIN; HUMANS; HYALURONIC ACID; HYDROGELS; MALE; MICE; MICE, INBRED BALB C; PLATELET-DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 49549112727     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.1080/10717540802035442     Document Type: Article

References (21)

1. Butterworth, P., Baum, H., and Porter, J. 1967. A modification of the Ellman procedure for the estimation of protein sulfhydryl groups. Arch. Biochem. Biophys. 118:716-723.
2. Elbert, D.L., and Hubbell, J.A. 2001. Conjugate addition reactions combined with free-radical cross-linking for the design of materials for tissue engineering. Biomacromolecules 2:430-431.
3. Godspodarowicz, D., and Cheng, J. 1986. Heparin protects basic and acidic FGF from inactivation. J . Cell Physiol. 128:475-484.
4. Liu, Y., Ahmad, S., Shu, X.Z., Sanders, R.K., Kopesec, S.A., and Prestwich, G.D. 2006. Accelerated repair of cortical bone defects using a synthetic extracellular matrix to deliver human demineralized bone matrix. J . Orthoped. Res. 24:1454-1462.
5. Liu, Y., Shu, X.Z., and Prestwich, G.D. 2005. Biocompatibility and stability of disulfide-crosslinked hyaluronan films. Biomaterials 26:4737-4746.
6. Luo, Y., and Prestwich, G.D. 2001. Novel biomaterials for drug delivery. Exp. Opin. Ther. Patents 11:1395-1410.
7. Peattie, R.A., Nayate, A.P., Firpo, M.A., Shao, Y., Shelby, J., Fisher, R.J., and Prestwich, G.D. 2004. Stimulation of in vivo angiogenesis by cytokine-loaded hyaluronic acid hydrogel implants. Biomaterials 25:2789-2798.
8. Peattie, R.A., Rieke, E.R., Hewett, E.M., Fisher, R.J., Shu, X.Z., and Prestwich, G.D. 2006. Dual growth factor-induced angiogenesis in vivo using hyaluronan hydrogel implants. Biomaterials 27:1868-1875.
9. Pike, D.B., Cai, S., Pomraning, K.R., Firpo, M.A., Fisher, R.J., Shu, X.Z., Prestwich, G.D., and Peattie, R.A. 2006. Heparin-regulated release of growth factors in vitro and angiogenic response in vivo to implanted hyaluronan hydrogels containing VEGF and bFGF. Biomaterials 27:5242-5251.
10. Pouyani, T., Harbison, G.S., and Prestwich, G.D. 1994. Novel hydrogels of hyaluronic acid: synthesis, surface morphology, and solid-state NMR. J . Am. Chem. Soc. 116:7515-7522.
11. Pouyani, T., and Prestwich, G.D. 1994. Functionalized derivatives of hyaluronic acid oligosaccharides: drug carriers and novel biomaterials. Bioconj. Chem. 5:339-347.
12. Prestwich, G.D., Shu, X.Z., Liu, Y., Cai, S., Walsh, J.F., Hughes, C.W., Kirker, K.R., Orlandi, R.R., Park, A.H., Thibeault, S.L., and Smith, M.E. 2006. Injectable synthetic extracellular matrices for tissue engineering and repair. Adv. Exp. Med. Biol. 585:125-133.
13. Prestwich, G.D., Shu, X.Z., Liu, Y., Kirker, K.R., Li, H., Shelby, J., Morris, S.E., and Gray, S.D. 2005. In situ crosslinkable synthetic extracellular matrices for tissue repair and prevention of surgical adhesions. In Hyaluronan: structure, metabolism, Biological Activities, Therapeutic Applications, vol. I. ed. Balazs, E. A., and Hascall, V. C. Edgewater, N J: Matrix Biology Institute, 409-414.
14. Prestwich, G.D., and Vercruysse, K.P. 1998. Therapeutic applications of hyaluronic acid and hyaluronan derivatives. Pharm. Sci. Technol. Today 1:42-43.
15. Robinson, C.J., and Stringer, S.E. 2001. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J. Cell Sci. 114:853-865.
16. Shu, X.Z., Ghosh, K., Liu, Y., Palumbo, F.S., Luo, Y., Clark, R.A., and Prestwich, G.D. 2004a. Attachment and spreading of fibroblasts on an RGD peptide-modified injectable hyaluronan hydrogel. J. Biomed. Mater. Res. 68A:365-375.
17. Shu, X.Z., Liu, Y., Palumbo, F.S., Luo, Y., and Prestwich, G.D. 2004b, In situ crosslinkable hyaluronan hydrogels for tissue engineering. Biomaterials 25:1339-1348.
18. Shu, X.Z., Liu, Y., Roberts, M.C., and Prestwich, G.D. 2002 Disulfide crosslinked hyaluronan hydrogels. Biomacromolecules 3:1304-1311.
19. Soker, S., Svahn, C.M., and Neufeld, G. 1993.Vascular endothelial growth factor is inactivated by binding to alpha 2-macroglobulin and the binding is inhibited by heparin. J. Biol. Chem. 268:7685-7691.
20. Vercruysse, K.P., Marecak, D.M., Marecek, J.F., and Prestwich, G.D. 1997. Synthesis and in vitro degradation of new polyvalent hydrazide cross-linked hydrogels of hyaluronic acid. Bioconjug. Chem. 8:686-94.
21. Wissink, M.J.B., Beernink, R., Poot, A.A., Engbers, G.H.M., Beugeling, T., van Aken, W.G., and Feijen, J. 2000 Improved endothelialization of vascular grafts by local release of growth factor from heparinized collagen matrices. J. Control. Rel. 64:103-114.